45 recruiting, 21 not yet recruiting, 1 completed, 1 enrolling by invitation. 62 Phase 2, 18 Phase 1, 2 Phase 3.
Follow Ivonescimab: new trials by email Literature Review of Ivonescimab trials Research Report on Ivonescimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL) Ivonescimab - Adrenocortical Carcinoma, Pheochromocytoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2027-02-07 | 2026-09-18 |
| A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA) Ivonescimab, IP PTX - Phase II, Ivonescimab | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 30 | 2027-01-16 | 2026-08-27 |
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer Biospecimen Collection, Computed Tomography, Fluorouracil - Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 30 | 2026-12-01 | 2026-09-02 |
| Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 in Combination With Ivonescimab in Sq-NSCLC Patients EVM14, Ivonescimab - Squamous Non-Small Cell Lung Cancer sqNSCLC | Phase 1 | Not yet recruiting | Everest Medicines (Beijing) Co., Ltd. | 13 | 2026-11-01 | 2026-09-11 |
| Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets Ivonescimab, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 158 | 2026-11-01 | 2026-06-04 |
| A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer Ivonescimab (dose level 1) combined with Cadonilimab, Ivonescimab (dose level 2) combined with Cadonilimab, Ivonescimab combined with Ipilimumab - Renal Cell Carcinoma, Clear Cell | Phase 2 | Not yet recruiting | Summit Therapeutics | 100 | 2026-10-19 | 2026-10-16 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors SYS6088, Regorafenib, Ivonescimab - Advanced/Metastatic Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 140 | 2026-10-03 | 2026-10-05 |
| A Phase II Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conversion Therapy for Biliary Tract Cancer Ivonescimab, GEMOX Regimen - Biliary Tract Cancer (BTC) | Phase 2 | Recruiting | Haitao Zhao, MD | 87 | 2026-10-01 | 2026-10-02 |
| Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Localized Clear Cell Renal Cell Carcinoma, Resectable Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 31 | 2026-10-01 | 2026-08-05 |
| Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC Paclitaxel Polymeric Micelles, Ivonescimab - SCLC, Recurrent | Phase 2 | Not yet recruiting | Shaodong Hong | 47 | 2026-10-01 | 2026-09-15 |
| Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial) Biospecimen Collection, Computed Tomography, Ivonescimab - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Recruiting | SWOG Cancer Research Network | 117 | 2026-09-22 | 2026-10-13 |
| A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103) Risvutatug rezetecan, Ivonescimab - Neoplasms, Lung | Phase 1 / Phase 2 | Recruiting | GlaxoSmithKline | 184 | 2026-09-09 | 2026-09-23 |
| Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC Carboplatin, Docetaxel, Doxorubicin - Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Not yet recruiting | University of Kansas Medical Center | 110 | 2026-09-01 | 2026-08-04 |
| Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases Ivonescimab, Bevacizumab, FOLFIRI Protocol - Metastatic Colorectal Cancer | Phase 2 | Not yet recruiting | UNICANCER | 130 | 2026-08-31 | 2026-05-19 |
| Pilot Study of Ivonescimab in Advanced/Metastatic Cutaneous Angiosarcoma Ivonescimab - Cutaneous Angiosarcoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 10 | 2026-08-19 | 2026-08-25 |
| Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients Ivonescimab +mFOLFOXIRI +celecoxib - Colorectal Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 45 | 2026-08-10 | 2026-09-09 |
| A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer AK138D1, Ivonescimab, Carboplatin - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Akeso | 265 | 2026-07-07 | 2026-07-29 |
| Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities Trastuzumab Rezetecan, ivonescimab - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 30 | 2026-07-01 | 2026-06-05 |
| A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer AK138D1, Ivonescimab, treatment of physician's choice - Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Akeso | 286 | 2026-06-06 | 2026-04-30 |
Showing 20 of 69. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (16) · Colorectal Neoplasms (6) · Small Cell Lung Carcinoma (6) · Breast Neoplasms (4) · Lung Neoplasms (4) · Triple Negative Breast Neoplasms (4) · Carcinoma, Renal Cell (3) · Biliary Tract Neoplasms (2) · Cholangiocarcinoma (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Pancreatic Neoplasms (2) · Recurrence (2) · Adenocarcinoma (1) · Adenocarcinoma Of Esophagus (1)
M.D. Anderson Cancer Center (9) · Akeso (6) · Memorial Sloan Kettering Cancer Center (6) · Sun Yat-sen University (5) · Fudan University (4) · UNICANCER (3) · City of Hope Medical Center (2) · Massachusetts General Hospital (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · CSPC Megalith Biopharmaceutical Co.,Ltd. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Cedars-Sinai Medical Center (1) · Dana-Farber Cancer Institute (1) · ECOG-ACRIN Cancer Research Group (1) · European Organisation for Research and Treatment of Cancer - EORTC (1)
China (28) · United States (26) · France (5) · Austria (1) · Germany (1) · Greece (1) · Italy (1) · Japan (1) · Netherlands (1) · Slovenia (1) · Spain (1) · United Kingdom (1)
Anuj D Patel, MD (1) · Aung Naing, MD (1) · Beth Helmink, MD (1) · David Malka, MD (1) · Deirdre J Cohen (1) · Fan Yang (1) · Fei Ma (1) · Helena Yu, MD (1) · Ivan Borbath, MD (1) · Jason Mouabbi, MD (1) · Jessics J Lin, MD (1) · Jianjun Zhang, MD (1) · Jinbo Yue, Doctor (1) · John Bridgewater, MD (1)
PMID 37879536, PMID 38362377, PMID 38642937, PMID 40057343, PMID 40528044, PMID 41125109, PMID 42669571
2025 (2), P30CA033572 (2), U10CA180820 (1), U10CA180888 (1)